PUBLIC HEALTH SERVICE Sample Clauses

PUBLIC HEALTH SERVICE. PATENT LICENSE AGREEMENT – EXCLUSIVE This Agreement is based on the model Patent License Exclusive Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). This Cover Page identifies the Parties to this Agreement: The U.S. Department of Health and Human Services, as represented by The National Cancer Institute an Institute or Center (hereinafter referred to as the “IC”) of the NIH and Senti Biosciences, Inc., hereinafter referred to as the “Licensee”, having offices at 0 Xxxxxxxxx Xx., Xxxxx Xxxxx, Xxxxx Xxx Xxxxxxxxx, XX 00000, And operating under the laws of Delaware. Tax ID No.: 00-0000000 For the IC internal use only: License Number: License Application Number: [***] Serial Number(s) of Licensed Patent(s) or Patent Application(s):
Sample 1
AutoNDA by SimpleDocs
PUBLIC HEALTH SERVICE. First Amendment This Agreement is based on the model Amendment Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). This Cover Page identifies the Parties to this Agreement: The U.S. Department of Health and Human Services, as represented by The National Eye Institute (NEI), an Institute or Center (hereinafter referred to as the “IC”) of the NIH and Curative Biotechnology (Formerly dba Connectyx Technologies Holdings Group, Inc.) hereinafter referred to as the “Licensee”, having offices at 1000 XX Xxxxxxxxx Xxxxxxxxx, Xxxxx 000, Xxxx Xxxxx, XX 00000, created and operating under the laws of Florida. Tax ID No.: 20-0000000
Sample 1
PUBLIC HEALTH SERVICE. 7. Asset Purchase Agreement dated December 2, 1996 between Connetics and SKB
Sample 1
PUBLIC HEALTH SERVICE. Seller will calculate and submit the Q4 2012 PHS covered entity pricing and Q1 2013 PHS covered entity pricing. Purchaser will add the product to the price list upon Closing and Seller will delete the product effective October 1, 2012.
Sample 1
PUBLIC HEALTH SERVICE. NON-EXCLUSIVE PATENT and BIOLOGICAL MATERIALS LICENSE AGREEMENT FOR INTERNAL RESEARCH USE This Agreement is based on the model Non-Exclusive Patent Internal Use Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). This Cover Page identifies the Parties to this Agreement: The U.S. Department of Health and Human Services, as represented by National Institute of Allergy and Infectious Diseases, an Institute or Center (hereinafter referred to as the “IC”) of the NIH and GeoVax Inc., hereinafter referred to as the “Licensee”, having offices at 1000 Xxxx Xxxx Xx., Xxx.000, Xxxxxx, Xxxxxxx 00000, created and operating under the laws of Georgia, United States of America. Tax ID No. : 50-0000000 For IC’s internal use only: License Number: L-243-2020-0 License Application Number: A-411-2020 Serial Number(s) of Licensed Patent(s) or Patent Application(s): Appendix A Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): N/A Additional Remarks: N/A Public Benefit(s): Novel therapeutics may be developed using a recombinant MVA platform. This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Licensed Products, Processes, Territory, Field of Use and Termination), Appendix C (Royalties), and Appendix D (Royalty Payment Options). The IC and the Licensee agree as follows:
Sample 1
PUBLIC HEALTH SERVICE. If the Recipient does not have an assurance and will be utilizing a subcontractor to perform the animal work, then the Recipient and subcontractor must have an Inter- Institutional Assurance in place to allow the Recipient to utilize the assurance of the subcontractor to meet the Government's requirements for assurance. The request for this negotiation of this assurance must be submitted to OLAW by the Government on behalf of the Recipient.
Sample 1
PUBLIC HEALTH SERVICE. PATENT LICENSE AGREEMENT NONEXCLUSIVE SUBLICENSABLE This Agreement is based on the model Patent License Non-Exclusive Sublicensable Agreement adopted by the U.S. Public Health Service (“PHS”) Technology Transfer Policy Board for use by components of the National Institutes of Health (“NIH”), the Centers for Disease Control and Prevention (“CDC”), and the Food and Drug Administration (“FDA”), which are agencies of the PHS within the Department of Health and Human Services (“HHS”). This Cover Page identifies the Parties to this Agreement: The U.S. Department of Health and Human Services, as represented by The National Heart, Lung, and Blood Institute (NHLBI) an Institute or Center (hereinafter referred to as the “IC”) of the NIH and Torus Therapeutics, Inc., hereinafter referred to as the “Licensee”, having offices at 000 Xxxxxxxxxx Xxxxxx, Xxxxxxxxx, XX 00000, created and operating under the laws of the State of Delaware, United States of America Tax ID No.: 000000000 For the IC’s internal use only License Number: L-124-2017/0 License Application Number: A-084-2017 Serial Number(s) of Licensed Patent(s) or Patent Application(s): O/Ref Country Application N° Status [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] [**] All entitled: [**]. HHS Reference: E-241-2010 Licensee: Torus Therapeutics Cooperative Research and Development Agreement (CRADA) Number (if a subject invention): N/A Additional Remarks: N/A Public Benefit(s): Development of Gene Therapy Products This Patent License Agreement, hereinafter referred to as the “Agreement”, consists of this Cover Page, an attached Agreement, a Signature Page, Appendix A (List of Patent(s) or Patent Application(s)), Appendix B (Fields of Use and Territory), Appendix C (Royalties), Appendix D 15A-084-2017; L-1242017/0 CONFIDENTIAL NIH Patent License Agreement Nonexclusive – Sublicensable Model 10-2015 ((Benchmarks and Performance), Appendix E (Commercial Development Plan), Appendix F (Example Royalty Report), and Appendix G (Royalty Payment Options. The IC and the Licensee agree as follows:
Sample 1
AutoNDA by SimpleDocs
PUBLIC HEALTH SERVICE. If the Recipient does not have an assurance and will be utilizing a Sub-recipient to perform the animal work then the Recipient and Sub- recipient must have an Inter-Institutional Assurance in place to allow the Recipient to utilize the assurance of the Sub-recipient to meet the DHHS requirements for assurance. The request for this negotiation of this assurance must be submitted to OLAW by BARDA on behalf of the Recipient. The PHS Policy requires that Assured institutions base their programs of animal care and use on the Guide for the Care and Use of Laboratory Animals http://www.nap.edu/readingroom/books/labxxxx/ xxx xxxx xxxx xxxxxx with the regulations (9 CFR, Subchapter A) http://awic.nal.usda.gov/final-rules-anixxx-xxxxxxx-0-xxx-xxxxx-0-2-and-3 issued by the USDA under the Animal Welfare Act. The Guide may differ from USDA regulations in some respects. Compliance with the USDA regulations is an absolute requirement of this Policy. The Association for Assessment and Accreditation of Laboratory Animal Care International (AAALAC) http://www.aaalac.org is a professional xxxxxxxxxxxx xxxx xxxpects and evaluates programs of animal care for institutions at their request. Those that meet the high standards are given the accredited status. As of the 2002 revision of the PHS Policy, the only accrediting body recognized by PHS is the AAALAC. While AAALAC accreditation is not required to conduct biomedical research, it is highly desirable. AAALAC uses the Guide as their primary evaluation tool. They also use the Guide for the Care and Use of Agricultural Animals in Agricultural Research and Teaching. It is published by the Federated of Animal Science Societies http://www.fass.org.
Sample 1
PUBLIC HEALTH SERVICE. PITS INTERINSTITUTIONAL AGREEMENT
Sample 1

Related to PUBLIC HEALTH SERVICE

  • Health and Safety C8.1 The Contractor shall promptly notify the Authority of any health and safety hazards which may arise in connection with the performance of the Contract. The Authority shall promptly notify the Contractor of any health and safety hazards which may exist or arise at the Authority’s Premises and which may affect the Contractor in the performance of the Contract.

  • Employment and Labor Relations Neither the Borrower nor any of its Subsidiaries is engaged in any unfair labor practice that, either individually or in the aggregate, could reasonably be expected to have a Material Adverse Effect. There is (i) no unfair labor practice complaint pending against the Borrower or any of its Subsidiaries or, to the knowledge of the Borrower, threatened against any of them, before the National Labor Relations Board, and no grievance or arbitration proceeding arising out of or under any collective bargaining agreement is so pending against the Borrower or any of its Subsidiaries or, to the knowledge of the Borrower, threatened against any of them, (ii) no strike, labor dispute, slowdown or stoppage pending against the Borrower or any of its Subsidiaries or, to the knowledge of the Borrower, threatened against the Borrower or any of its Subsidiaries, (iii) no union representation question exists with respect to the employees of the Borrower or any of its Subsidiaries, (iv) no equal employment opportunity charges or other claims of employment discrimination are pending or, to the Borrower’s knowledge, threatened against the Borrower or any of its Subsidiaries, and (v) no wage and hour department investigation has been made of the Borrower or any of its Subsidiaries, except (with respect to any matter specified in clauses (i) through (v) above, either individually or in the aggregate) such as could not reasonably be expected to have a Material Adverse Effect.

  • Whistleblower Protections and Trade Secrets Notwithstanding anything to the contrary contained herein, nothing in this Agreement prohibits Executive from reporting possible violations of federal law or regulation to any United States governmental agency or entity in accordance with the provisions of and rules promulgated under Section 21F of the Securities Exchange Act of 1934 or Section 806 of the Xxxxxxxx-Xxxxx Act of 2002, or any other whistleblower protection provisions of state or federal law or regulation (including the right to receive an award for information provided to any such government agencies). Furthermore, in accordance with 18 U.S.C. § 1833, notwithstanding anything to the contrary in this Agreement: (i) Executive shall not be in breach of this Agreement, and shall not be held criminally or civilly liable under any federal or state trade secret law (x) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (y) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (ii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive’s attorney, and may use the trade secret information in the court proceeding, if Executive files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order.

  • Privacy Act If performance involves design, development or operation of a system of records on individuals, this Agreement incorporates by reference FAR 52.224-1 Privacy Act Notification (Apr 1984) and FAR 52.224-2 Privacy Act (Apr 1984).

  • Labor Relations No labor dispute exists or, to the knowledge of the Company, is imminent with respect to any of the employees of the Company, which could reasonably be expected to result in a Material Adverse Effect. None of the Company’s or its Subsidiaries’ employees is a member of a union that relates to such employee’s relationship with the Company or such Subsidiary, and neither the Company nor any of its Subsidiaries is a party to a collective bargaining agreement, and the Company and its Subsidiaries believe that their relationships with their employees are good. To the knowledge of the Company, no executive officer of the Company or any Subsidiary, is, or is now expected to be, in violation of any material term of any employment contract, confidentiality, disclosure or proprietary information agreement or non-competition agreement, or any other contract or agreement or any restrictive covenant in favor of any third party, and the continued employment of each such executive officer does not subject the Company or any of its Subsidiaries to any liability with respect to any of the foregoing matters. The Company and its Subsidiaries are in compliance with all U.S. federal, state, local and foreign laws and regulations relating to employment and employment practices, terms and conditions of employment and wages and hours, except where the failure to be in compliance could not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

  • Environment, Health, and Safety 24.4.1. The Supplier and its staff (and/or any sub-supplier and/or subcontractor) shall comply with the laws and regulations in force related to protection of the environment, the health and safety instructions applicable to the Goods and Services performed pursuant to the Contract and especially, if appropriate, to the Goodsand Services performedon any Site by a third company.

Time is Money Join Law Insider Premium to draft better contracts faster.